Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Abstract The advent of genomics has led to the identification of specific “driver” mutations in oncogenic kinases, and the development of targeted small molecule inhibitors to block their tumor-driving functions. These specific inhibitors have been a clinical success, and often significantly prolong...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-03-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-017-0007-0 |